EBRT

Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer

Retrieved on: 
Monday, March 4, 2024
Head, Neck, Recurrence, Toxicity, Anemia, Completeness, Radiation, SPECT/CT, Chemoradiotherapy, EBRT, Macroglobulinemia, Lymphocytopenia, Thrombocytopenia, Patient, Neutropenia, Survival, Poster, Cytopenia, Cancer, Pharmaceutical industry

The twelve patients treated for locoregionally recurrent head and neck squamous cell carcinoma previously received chemoradiation alone (42%), surgery (58%) or surgery combined with radiation or chemoradiation (92%).

Key Points: 
  • The twelve patients treated for locoregionally recurrent head and neck squamous cell carcinoma previously received chemoradiation alone (42%), surgery (58%) or surgery combined with radiation or chemoradiation (92%).
  • The data were presented in a poster at the 2024 Multidisciplinary Head and Neck Cancers Symposium held February 29-March 2, 2024, in Phoenix, AZ.
  • Complete remission was achieved in 64% of patients, with an ORR of 73% (n=11).
  • Observed adverse events were consistent with the known toxicity profile of iopofosine I 131, with cytopenias being the most common with all patients recovering.

Bayer Reveals Latest Prostate Cancer Data at 2024 ASCO GU Cancers Symposium

Retrieved on: 
Wednesday, January 17, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Patient, BCR, CSPC, Prostate cancer, Hospital, Metastasis, ASCO, EBRT, Systematic review, Safety, Society, Docetaxel, Observational study, ADT, Phase, Cancer, Medical imaging

Bayer will present new data across its prostate cancer portfolio at the upcoming American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place January 25-27, 2024 in San Francisco, California.

Key Points: 
  • Bayer will present new data across its prostate cancer portfolio at the upcoming American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place January 25-27, 2024 in San Francisco, California.
  • These presentations underscore Bayer’s commitment to advance prostate cancer care.
  • NUBEQA® (darolutamide) data includes post hoc sensitivity analyses from the Phase III ARASENS trial, evaluating overall survival (OS) with NUBEQA and androgen deprivation therapy (ADT) and docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC) patients accounting for subsequent therapy.
  • Abstract title: Safety outcomes in patients with metastatic castration-resistant prostate cancer treated with radium-223 following external beam radiation therapy: REASSURE US subset

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer

Retrieved on: 
Friday, January 12, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Histopathology, Weight loss, Gynaecology, Bevacizumab, Cisplatin, Hypothyroidism, University, Cancer, Risk, COVID-19, Diarrhea, Hyperthyroidism, Brachytherapy, Neoplasm, Perforated ulcer, Hepatitis, FIGO, CRT, Pyelonephritis, Colitis, Vagina, ClinicalTrials.gov, PD-L1, RECIST, Disease, Patient, Fever, CPS, Chemoradiotherapy, Vomiting, MRK, Death, Nephritis, Progression-free survival, OS, Radiation, Anemia, Survival, EBRT, Abdominal pain, Intraparenchymal hemorrhage, Uterus, Cervical cancer, Constipation, PFS, Fatal, Obstetrics, Hematopoietic stem cell transplantation, Pneumonitis, Nausea, Pelvic pain, Dysuria, Fatigue, GOG, Arm, Rash, Food, Merck & Co., Sepsis, Toxicity, News, Urinary tract infection, Appetite, Pharmaceutical industry

Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.

Key Points: 
  • Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.
  • “Building on the established role of KEYTRUDA in advanced cervical cancer, KEYTRUDA plus chemoradiotherapy is now the first anti-PD-1-based regimen approved in the U.S. for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer regardless of PD-L1 expression,” said Dr. Gursel Aktan, vice president, global clinical development, Merck Research Laboratories.
  • The trial enrolled 1,060 patients with cervical cancer who had not previously received any definitive surgery, radiation, or systemic therapy for cervical cancer.
  • In the exploratory subgroup analysis of 596 patients with FIGO 2014 Stage III-IVA disease, 61 patients (21%) in the KEYTRUDA plus CRT arm (n=293) experienced a PFS event versus 94 patients (31%) in the placebo plus CRT arm (n=303).

Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar

Retrieved on: 
Monday, November 20, 2023
MTD, Neurology, Neoplasm, PSTV, Index, IND, University of Texas System, Catheter, SNO, EBRT, Neuro-oncology, Plus, Neuro, Decompression (diving), MD, Doctor of Philosophy, Therapy, Clinical trial, Standard of care, CED, Society, Annual general meeting, Bevacizumab, MFD, Plus Therapeutics, NIH, Patient, University, Safety, Phase II, SOC, Radiation, KOL, Pharmaceutical industry

The Company is hosting a virtual key opinion leader (KOL) webinar to discuss the data today at 10:00 am ET.

Key Points: 
  • The Company is hosting a virtual key opinion leader (KOL) webinar to discuss the data today at 10:00 am ET.
  • Rhenium (186Re) obisbemeda continues to be generally safe and well tolerated, consistent with data accumulated in the Phase 1 trial.
  • Plus Therapeutics is hosting a virtual KOL event today, November 20, 2023 at 10:00 am ET to discuss the data presented at SNO.
  • A replay of the event will be available on Investor Relations section of the Plus Therapeutics website after the event.

Radiotherapy Market Worth $8.8 Billion | MarketsandMarkets

Retrieved on: 
Friday, November 10, 2023
EBRT, Research, Radiation, Prevalence, Incidence, Hitachi, Risk, Hospital, IsoRay, Patient, Radiation exposure, Brachytherapy, Medical tourism, Cancer, Pulse, R, Growth, MRI, Government, GE HealthCare, Medical imaging, Retail, Marketing

The external beam radiotherapy segment, by procedure, is expected to register the largest market share of the global radiotherapy systems market in 2023.

Key Points: 
  • The external beam radiotherapy segment, by procedure, is expected to register the largest market share of the global radiotherapy systems market in 2023.
  • Based on procedure, the radiotherapy market is segmented into external beam radiotherapy, internal beam radiotherapy/brachytherapy, and systemic radiotherapy.
  • Additionally rising medical tourism and entry of major market players in the Asia Pacific countries are likely to support the radiotherapy market growth in APAC.
  • ·  Newer and improved representation of financial information: In the latest edition of the Radiotherapy  market report, the market ranking analysis of top players in the Radiotherapy  market has been provided for base year (2022) by extensively studying the financial revenues generated by the major players operating in the Radiotherapy  market.

Merck’s KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy Significantly Improved Progression-Free Survival (PFS) Versus Concurrent Chemoradiotherapy Alone in Newly Diagnosed, High-Risk Locally Advanced Cervical Cancer

Retrieved on: 
Friday, October 20, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Bevacizumab, Neoplasm, FDA, Arm, PD-L1, Standard of care, Cervical cancer, Gynaecology, Hypothyroidism, Catholic higher education, Aes, NYSE, ESMO, Progression-free survival, Food, Trae tha Truth, Cisplatin, Congress, Chemoradiotherapy, MRK, PFS, European Society for Medical Oncology, Obstetrics, GOG, Brachytherapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, HIV disease progression rates, Creighton University School of Medicine, CPS, ClinicalTrials.gov, Merck & Co., Risk, EBRT, Immunotherapy, University, European Network for Health Technology Assessment, Woman, Safety, European Society of Gynaecological Oncology, Cancer, Patient, OS, Death, Pharmaceutical industry, Merck

Results from the trial showed that KEYTRUDA in combination with concurrent chemoradiotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to concurrent chemoradiotherapy alone for these patients.

Key Points: 
  • Results from the trial showed that KEYTRUDA in combination with concurrent chemoradiotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to concurrent chemoradiotherapy alone for these patients.
  • ET during a late-breaking abstract proffered paper session at the European Society for Medical Oncology (ESMO) Congress 2023 (abstract #LBA38).
  • After a median follow-up of 17.9 months (range, 0.9-31.0), the KEYTRUDA regimen reduced the risk of disease progression or death by 30% (HR=0.70 [95% CI, 0.55-0.89]; p=0.0020) versus concurrent chemoradiotherapy alone in these patients.
  • The 24-month PFS rate was 67.8% for patients who received the KEYTRUDA regimen compared to 57.3% for those who received concurrent chemoradiotherapy alone.

"Study Radiation Therapy With Erin" Podcast Fuels Global Interest as "2022-2023 Radiation Therapy Market Summary Report" is Released

Retrieved on: 
Wednesday, October 11, 2023
Diagnosis, Acquisition, Breast cancer, IMV, RT, Data analysis, Brachytherapy, Radiation, Keiser University, IGRT, Cancer, EBRT, OEM, Woman, Patient, Medical imaging

The 2022-2023 Radiation Therapy Market Summary Report is a meticulous compilation of data, presenting a panoramic view of key radiation therapy technologies, ranging from external beam radiation therapy (EBRT) and image-guided radiotherapy (IGRT) to brachytherapy equipment and sophisticated simulators.

Key Points: 
  • The 2022-2023 Radiation Therapy Market Summary Report is a meticulous compilation of data, presenting a panoramic view of key radiation therapy technologies, ranging from external beam radiation therapy (EBRT) and image-guided radiotherapy (IGRT) to brachytherapy equipment and sophisticated simulators.
  • Holistic View of Radiation Therapy: The report comprehensively covers the range of radiation therapy technologies used in treating cancer patients, highlighting trends in patient volume, installed equipment, market share, and more.
  • For businesses, entrepreneurs, and managers in the healthcare sector, the 2022-2023 Radiation Therapy Market Summary Report is more than just data; it's the roadmap to understanding and navigating the rapidly evolving world of radiation therapy.
  • To invest in your business's future and to gain a robust understanding of the radiation therapy market, make sure to acquire the 2022-2023 Radiation Therapy Market Summary Report.

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Retrieved on: 
Wednesday, September 20, 2023
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, MSD, Bevacizumab, Progression-free survival, Neoplasm, MRK, Immunotherapy, PFS, Merck & Co., HIV disease progression rates, Cervical cancer, Patient, CPS, Brachytherapy, PDUFA, EBRT, FDA, Chemoradiotherapy, Recurrence, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PD-L1, NYSE, Food, Disease, Pharmaceutical industry, Merck

The sBLA is based on data from the KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, in which KEYTRUDA plus concurrent chemoradiotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to concurrent chemoradiotherapy alone.

Key Points: 
  • The sBLA is based on data from the KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, in which KEYTRUDA plus concurrent chemoradiotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to concurrent chemoradiotherapy alone.
  • If approved, this would be Merck’s third approved indication in cervical cancer and first in an earlier stage of the disease.
  • The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of January 20, 2024.
  • “If approved, KEYTRUDA will be the first immunotherapy available for patients with newly diagnosed high-risk locally advanced cervical cancer.

GT Medical Technologies Awarded the Arizona Bioscience Company of the Year for Disrupting the Status Quo in Brain Tumor Treatment

Retrieved on: 
Tuesday, August 15, 2023
Brain, Radiation, GT, Neoplasm, Neurosurgery, Patient, EBRT, Get Behind Me Satan, Anniversary Celebration, FDA, Meningioma, Medical imaging

Driven to improve the lives of patients with brain tumors, a group of brain tumor specialists and medical device experts joined forces to reimagine brain brachytherapy for operable glioblastomas (GBMs), meningiomas, and brain metastases.

Key Points: 
  • Driven to improve the lives of patients with brain tumors, a group of brain tumor specialists and medical device experts joined forces to reimagine brain brachytherapy for operable glioblastomas (GBMs), meningiomas, and brain metastases.
  • For patients with operable brain tumors, neurosurgeons seek a "maximal safe resection" of the tumor, which means they remove as much of the tumor as possible while preserving healthy brain tissue.
  • However, resecting all the brain tissue that may harbor cancer cells is limited because of the location in the brain.
  • This Surgically Targeted Radiation Therapy (STaRT) is a one-and-done radiation treatment that allows patients to get back to their daily lives sooner.

GT Medical Technologies Highlights Glioblastoma (GBM) Awareness Day July 19 and Ongoing GammaTile® Therapy Clinical Studies

Retrieved on: 
Wednesday, July 19, 2023
Brain, Radiation, REP, GBM, Progression-free survival, Hair loss, Health technology, Survival, Clinical trial, Glioblastoma, Hospital, Patient, EBRT, Neoplasm, Get Behind Me Satan, FDA, Safety, Medical imaging

In a single treatment, GammaTile Therapy eliminates the EBRT treatment delay and gives patients a head start in preventing tumor regrowth.

Key Points: 
  • In a single treatment, GammaTile Therapy eliminates the EBRT treatment delay and gives patients a head start in preventing tumor regrowth.
  • "With GammaTile Therapy, patients can benefit from a single, targeted immediate radiation treatment that gets them back to their lives sooner.
  • Advancements like GammaTile Therapy are made possible by patients who volunteer to participate in clinical studies to further validate the safety and effectiveness of this therapy.
  • GT Medical Technologies is sponsoring ongoing studies at leading brain tumor treatment centers nationwide for patients with GBMs and other brain tumors.